Biolex finances hepatits C treatment

BY MONICA CHEN : The Herald-Sun
Oct 7, 2008

PITTSBORO -- After withdrawing its initial public offering in February, biopharmaceutical company Biolex Therapeutics Inc. has come back strong with the closing of a $60 million Series D financing and acquisition of commercial rights to a hepatitis C treatment.

-----------------------------------------------------------------------------------------------------------------------------

The requested content is restricted to registered users.

Registered Users  Already a Member? User Name: Password: Store password and login.   Forgotten your User Name or Password? Just enter your e-mail address in the box below and we will send your information to you right away. Email:   If you do not receive an email from webmail@southernheadlines.com within 30 minutes with your password, be sure to check your Junk Mail folder. Having trouble signing in? Contact us.

Not a Registered User? Registration is FREE and helps us to better know and serve our readers. All personal information provided is confidential and will not be sold to a third party. Fill out the form below: Note: Fields marked with an (*) are required! *Create a Member ID: *E-mail Address: *Year of Birth: *First Name: *Last Name: *Home Phone: *Address: *City: *State: ---Select your state--- Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware District of Columbia Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Puerto Rico Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington (state) West Virginia Wisconsin Wyoming *Zip Code:

:: Copyright 2008 :: :: Terms of Use ::